Please assess the completion status of the following clinical trial:

Trial Title: Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ①Patients must have received radiation therapy for histologically confirmed nasopharyngeal carcinoma.~  * Prior irradiation \>/= 6 months prior to study entry.~    * Radiographic evidence to support the diagnosis of radiation-induced temporal lobe necrosis without tumor recurrence(15).~      * Age\>/= 18 years.~        * No evidence of very high intracranial pressure that suggests brain hernia and need surgery.~          * Fertile women who are willing to take contraception during the trial.~            * Routine laboratory studies with bilirubin \</=2 \* upper limits of normal (ULN), aspartate aminotransferase (AST or SGOT) \< 2 \* ULN, creatinine \<1.5 \* ULN, red-cell count \>/= 4,000 per cubic millimeter; white-cell count \>/=1500 per cubic millimeter, platelets \>/= 75,000 per cubic millimeter; Hb \>/=9.0. prothrombin time(PT), activated partial thromboplastin time(APTT),international normalized ratio(INR) in a normal range.~              * Ability to understand and willingness to sign a written informed consent document.~Exclusion Criteria:~* ①Tumor recurrence or metastases.~  * Diseases of central nervous system, such as cerebral vascular events, inflammatory, degenerative disease, and significant cardiovascular diseases.~    * Severe systemic diseases.~      * History of anaphylactic response to edaravone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edaravone group (Type: EXPERIMENTAL): Edaravone was used at a dose of 30mg,intravenously, twice per day, for 14 days. All patients also received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
- Control group (Type: EXPERIMENTAL): All patients in this group received common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.

Based on this trial design, predict the completion outcome and termination type (if applicable).